Atea Pharmaceuticals Inc (AVIR)
3.25
+0.09
(+2.85%)
USD |
NASDAQ |
Nov 21, 16:00
3.24
-0.01
(-0.31%)
After-Hours: 20:00
Atea Pharmaceuticals Enterprise Value: -208.31M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -208.31M |
| November 20, 2024 | -215.91M |
| November 19, 2024 | -217.60M |
| November 18, 2024 | -215.06M |
| November 15, 2024 | -210.84M |
| November 14, 2024 | -203.24M |
| November 13, 2024 | -199.86M |
| November 12, 2024 | -201.55M |
| November 11, 2024 | -199.02M |
| November 08, 2024 | -187.19M |
| November 07, 2024 | -192.26M |
| November 06, 2024 | -180.44M |
| November 05, 2024 | -199.02M |
| November 04, 2024 | -199.86M |
| November 01, 2024 | -204.93M |
| October 31, 2024 | -209.15M |
| October 30, 2024 | -205.77M |
| October 29, 2024 | -196.48M |
| October 28, 2024 | -193.95M |
| October 25, 2024 | -199.86M |
| October 24, 2024 | -197.33M |
| October 23, 2024 | -188.88M |
| October 22, 2024 | -182.12M |
| October 21, 2024 | -179.59M |
| October 18, 2024 | -160.16M |
| Date | Value |
|---|---|
| October 17, 2024 | -167.77M |
| October 16, 2024 | -164.39M |
| October 15, 2024 | -182.97M |
| October 14, 2024 | -184.66M |
| October 11, 2024 | -188.88M |
| October 10, 2024 | -200.71M |
| October 09, 2024 | -195.64M |
| October 08, 2024 | -194.79M |
| October 07, 2024 | -194.79M |
| October 04, 2024 | -190.57M |
| October 03, 2024 | -201.55M |
| October 02, 2024 | -198.17M |
| October 01, 2024 | -201.55M |
| September 30, 2024 | -199.86M |
| September 27, 2024 | -211.80M |
| September 26, 2024 | -211.80M |
| September 25, 2024 | -212.65M |
| September 24, 2024 | -206.74M |
| September 23, 2024 | -210.96M |
| September 20, 2024 | -192.39M |
| September 19, 2024 | -179.72M |
| September 18, 2024 | -165.37M |
| September 17, 2024 | -162.84M |
| September 16, 2024 | -173.81M |
| September 13, 2024 | -175.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-396.68M
Minimum
Mar 24 2023
6.441B
Maximum
Feb 08 2021
446.28M
Average
-198.76M
Median
Enterprise Value Benchmarks
| McKesson Corp | 83.36B |
| Pfizer Inc | 199.35B |
| Doximity Inc | 8.156B |
| Immuneering Corp | 14.86M |
| CEL-SCI Corp | 36.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.15M |
| Total Expenses (Quarterly) | 37.20M |
| EPS Diluted (Quarterly) | -0.37 |
| Earnings Yield | -63.69% |
| Operating Earnings Yield | 50.68% |
| Normalized Earnings Yield | 41.85 |